Cart
sales@molnova.com
GSK343
CAS No. 1346704-33-3
GSK343 ( GSK343; GSK-343; GSK 343 )
Catalog No. M11407 CAS No. 1346704-33-3
GSK343 is a potent and selective EZH2 inhibitor with IC50 of 4 nM, showing 60 fold selectivity against EZH1.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 49 | In Stock |
|
| 10MG | 78 | In Stock |
|
| 25MG | 163 | In Stock |
|
| 50MG | 267 | In Stock |
|
| 100MG | 484 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK343
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK343 is a potent and selective EZH2 inhibitor with IC50 of 4 nM, showing 60 fold selectivity against EZH1.
-
DescriptionGSK343 is a potent and selective EZH2 inhibitor with IC50 of 4 nM, showing 60 fold selectivity against EZH1, and >1000 fold selectivity against other histone methyltransferases.
-
SynonymsGSK343; GSK-343; GSK 343
-
PathwayChromatin/Epigenetic
-
TargetHMTase
-
RecptorEZH1; EZH2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1346704-33-3
-
Formula Weight541.69
-
Molecular FormulaC31H39N7O2
-
Purity>98%(HPLC)
-
SolubilityEthanol: 4 mg/mL (7.38 mM); DMSO: 1 mg/mL warmed (1.84 mM)
-
SMILESO=C(C1=CC(C2=CC(N3CCN(C)CC3)=NC=C2)=CC4=C1C=NN4C(C)C)NCC5=C(CCC)C=C(C)NC5=O
-
Chemical Name1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-indazole-4-carboxamide.
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Verma SK, et al. ACS Med Chem Lett. 2012, 3, 1091-1096.
molnova catalog
related products
-
BIX 01294 Trihydroch...
BIX01294 is an inhibitor of G9a histone methyltransferase with IC50 of 2.7 μM in a cell-free assay.
-
EPZ-031686
A potent, selective, small molecule SMYD3 inhibitor (Biochem IC50=3 nM; Cell IC50= 36 nM).
-
CMP-5 hydrochloride
CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival.
